A South Korean company is preparing to bring its artificial intelligence platform to the United States, giving small biotech firms a new way to predict whether experimental drugs will succeed before they spend money on lab work. BasGenBio plans to sign a paid distribution agreement with Boston based Cambridge Scientific in June, opening its first sales route in the US for Deepcision, software that forecasts clinical trial outcomes.
The platform analyzes a compound’s chemical structure, disease indication and target protein, then calculates the probability of success across phase 1 through 4 clinical trials. It also provides ADMET profiling, off target analysis and SHAP based feature attribution, tools that assess how a drug may behave in the body and why the AI reached a particular prediction. According to the company, Deepcision is built on a 770,000 person multi-omics clinical cohort and 156,000 biobank samples.
In a retrospective test of about 30 drugs including approved medicines and candidates that failed during development, the platform matched known outcomes in approximately eight out of 10 cases. BasGenBio reviewed more than 100 clinical and biological measures in the test. The company says it does not simply predict success or failure but shows predicted values for each of those individual conditions. The software is offered as a subscription based service.
Cambridge Scientific operates biotech incubator labs and shared laboratory suites in the Boston area, serving many drug discovery startups and biotech companies. BasGenBio’s chief executive Tom Kim said Cambridge Scientific wanted to introduce simulation to improve the quality of experiments, rather than just selling lab equipment or reagents. The companies will co-host an online webinar this week to introduce Deepcision to Cambridge Scientific’s customers and partners. Participants will be able to apply to use the platform as beta testers after the session.
The companies plan to sign the paid distribution contract in June around the BIO International Convention in Boston. BasGenBio is also developing its own drug programs in androgenetic alopecia, sarcopenia and HDAC6 inhibitors, and operates additional AI platforms for target discovery, single cell analysis and clinical trial decision support. With the US partnership, the company aims to give smaller drug developers a practical tool to reduce unnecessary time, materials and experiment steps before moving into the lab.